Mirtazapine is an antidepressant medication belonging to the class of noradrenergic and specific serotonergic antidepressants (NaSSAs). It is supplied as a pill in strengths of 7.5 mg, 15 mg, and 30 mg. In Hong Kong, mirtazapine is a prescription-only drug and is regulated by the Department of Health. While the active ingredient is the same, it is marketed under various brand names such as Remeron.
Mirtazapine exerts its therapeutic effect through several mechanisms:
These actions collectively increase neurotransmitter activity in brain regions that regulate mood, anxiety, and sleep. The onset of antidepressant effect usually appears within 1-2 weeks, with full benefit emerging after 4-6 weeks of continued therapy.
Mirtazapine is FDA- and EMA-approved for the treatment of major depressive disorder (MDD) in adults. In Hong Kong, it is indicated for patients diagnosed with MDD who require an alternative to selective serotonin reuptake inhibitors (SSRIs) or who experience prominent insomnia or weight loss. The medication may also be prescribed for depressive symptoms associated with other psychiatric conditions when clinically justified.
Off-label use requires medical supervision, an individualized risk assessment, and should be discussed with a qualified healthcare professional.
Patients with a history of bipolar disorder should be monitored closely for manic switch.
Patients should disclose all prescription drugs, over-the-counter medications, supplements, and herbal products to their prescriber before starting mirtazapine.
Regular follow-up appointments allow dose adjustments and early detection of adverse effects.
This article provides educational information about mirtazapine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Mirtazapine is usually prescribed at night because its antihistamine effect often causes sedation. In some cases, a low dose (7.5 mg) may be taken in the morning if insomnia is not a concern, but this should only be done after a clinician evaluates the risk of daytime drowsiness.
Common generic tablets bear imprints such as “MIR-15” for 15 mg or “MIR-30” for 30 mg, while brand-name versions often display “RE-15” or “RE-30.” Imprint details can vary by manufacturer and region, so patients should verify with their pharmacist.
Mirtazapine can cause modest increases in blood pressure due to its noradrenergic activity. Patients with uncontrolled hypertension should have their blood pressure monitored and discuss risk-benefit considerations with their prescriber.
There is limited evidence suggesting that mirtazapine may modestly raise total cholesterol and triglycerides in some individuals. Routine lipid monitoring is not required unless the patient has pre-existing dyslipidemia.
Mirtazapine is not part of typical workplace drug-screen panels (e.g., for opioids, cannabis, amphetamines). However, specialized testing can detect it if specifically requested, which is uncommon.
Yes, but keep the medication in its original packaging with the prescription label. Carry a copy of the prescription or a physician’s letter, especially when traveling to countries with strict medication import regulations.
St. John’s wort is a serotonergic herb and may increase the risk of serotonin syndrome when combined with mirtazapine. Patients should avoid such combinations unless supervised by a healthcare professional.
Weight gain is a common side effect. Discuss dietary counseling and possible dose adjustment with your prescriber. In some cases, switching to an alternative antidepressant may be considered.
Tolerance to sedation can develop over several weeks, leading to reduced drowsiness. If persistent sleep disruption occurs, dose timing or a switch to a different agent may be advised by your clinician.
Mirtazapine has an elimination half-life of about 20-40 hours. It typically takes 4-5 half-lives (approximately 4-8 days) for the drug to be cleared, though clinical effects may diminish sooner. A tapering schedule helps minimize withdrawal symptoms.
